Revolution Medicines, Inc.
RVMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7 | $3 | $2 | $2 |
| - Cash | $1 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $7 | $3 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -67.3% | 20.4% | – |
| Gross Profit | -$1 | -$0 | -$0 | -$0 |
| % Margin | – | -3,451.3% | -615.3% | -536.1% |
| EBITDA | -$1 | -$0 | -$0 | -$0 |
| % Margin | – | -3,943.7% | -702.7% | -611.6% |
| Net Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | – | -3,768.3% | -703% | -636.6% |
| EPS Diluted | -3.58 | -3.86 | -3.08 | -2.47 |
| % Growth | 7.3% | -25.3% | -24.7% | – |
| Operating Cash Flow | -$1 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$1 | -$0 | -$0 | -$0 |